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Summary We determined the ability of the multidrug resistance (MDR) reversal agent cyclosporin-A to
increase anthracycline drug accumulation in colorectal tumour cells in vitro, using the technique of on-line flow
cytometry. Data of four previously untreated patients showed that cyclosporin-A can increase intracellular
net-uptake of daunorubicin.
A phase II study was initiated in 24 colorectal cancer patients. They received cyclosporin-A at a dose of
3 mg kg-' over 1 h as i.v. infusion, at 7 h and at 1 h preceding cytotoxic drug administration. At the end of
the second cyclosporin-A administration epidoxorubicin 90 mg m-2 was administered as i.v. bolus. Cycles were
repeated every 3 weeks. Median cyclosporin-A peak blood levels and levels at 18 h after cytotoxic drug
administration appeared to be 6248ngml-' and 1012ngml-' respectively. Only one partial response was
observed, despite these high cyclosporin-A levels. Cyclosporin-A did not cause major toxicity, only a 29%
incidence of hot flushes was observed. Epidoxorubicin toxicities were as expected but the frequency of severe
leucocytopenia was striking. This treatment schedule can not be considered active in colorectal cancer.
Despite the very intensive research for more effective agents
for the treatment of colorectal cancer, 5-fluorouracil (5-FU)
remains the most effective with a response rate of 5-15%
(Moertel, 1978; Chlebowski et al., 1980; Ehrlichman et al.,
1988; Doroshow et al., 1990). A more recent approach with
the addition of leucovorin to 5-FU indeed yields a higher
response rate, but this is achieved at the cost of increased
toxicity and without a meaningful survival benefit (Ehrlich-
man et al., 1988; Doroshow et al., 1990). A combination of
a-interferon and 5-FU may also improve the response rate
(Wadler et al., 1989).
Anthracyclines are considered inactive in this disease, the
highest response rates being achieved with 4'-epidoxorubicin
which yielded an overall response rate of 8% in 272 patients
(Falkson & Vorobiof, 1984). The reason of the inactivity of
this class of drugs may be due to the classical multidrug
resistance (MDR) phenotype, which includes:
(1) Cross-resistance to non-related anticancer drugs such as
anthracyclines, vinca alkaloids and podophyllotoxins.
(2) Decreased intracellular drug accumulation due to en-
hanced drug efflux, through an activated pump mech-
anism.
(3) Increased intracellular drug accumulation after exposure
to a variety of so called MDR reversal agents, such as
verapamil (Ozols & Cowan, 1986; Pastan & Gottesman,
1987) and cyclosporin-A (Herweijer et al., 1989; Nooter
et al., 1989) resulting in restoration of drug sensitivity.
(4) Assumed activity of an energy dependent unidirectional
drug efflux pump with broad substrate specificity (Pastan
& Gottesman, 1987). This drug pump is composed of a
transmembrane glycoprotein (P-glyco-protein) with a
molecular weight of 170 kDa and encoded by the mdrl
gene (Pastan & Gottesman, 1987; Shen et al., 1986).
Recently, RNA slot blot analysis revealed a high expres-
sion of the mdrl gene in 35 of 41 previously untreated
adenocarcinomas of the colon (Goldstein et al., 1989). In
addition, drug resistance in seven colon tumour cell lines
could be overcome by verapamil (Klohs & Steinkampf,
1988). Thus, the MDR phenotype may be present in the
majority of colon carcinomas.
The current hypothesis on the mode of action of MDR
reversal agents is that they restore drug accumulation by
competing for efflux through binding to P-glycoprotein.
However, clinical trials with verapamil in combination with
doxorubicin and vinblastine in several malignancies have
been disappointing (Ozols et al., 1987; Cairo et al., 1989;
Figueredo et al., 1990).
An explanation may be that verapamil cannot be given at
adequate doses because of clinical toxicity. In fact, the
documented concentrations required to overcome MDR in
vitro are much higher than those which are achieved with
daily doses of verapamil in cardiac patients (Fishman et al.,
1982). In several in vitro studies cyclosporin-A reversed
MDR more effectively than verapamil (Herweijer et al., 1989,
Nooter et al., 1989). Moreover, cyclosporin-A concentrations
required in vitro (Silbermann et al., 1989) can be reached in
vivo without toxicity.
Patients and methods
Drug uptake studies
Colon carcinoma cells were obtained from ascites. The pre-
sence of tumour cells was assessed by cytology. Cells were
spun down (200 g, 15 min), washed once, and resuspended in
RPMI-1640 medium. To determine the drug uptake kinetics
of these cells, they were incubated with daunorubicin at a
final concentration of 2 LM. Daunorubicin was chosen over
the clinically applied epidoxorubicin because of its faster
uptake kinetics. However, the same type of accumulation
curves can be obtained with all anthracycline drugs (unpub-
lished data).
A modified flow cytometer was used that enables uninter-
rupted monitoring of the scattering and fluorescence signals,
from the moment of drug addition up to a few hours
thereafter (Herweijer et al., 1989; Nooter, 1989). The cells
(2 x 105ml1' in RPMI-1640 medium without phenol red)
were kept at 37°C in a reaction vessel surrounded by a
thermostated water jacket and connected to the flow cuvette
of the flow cytometer. By means of air pressure the medium
containing the cells is forced through the flow cuvette. An
extra inlet in the reaction vessel allows for the addition of
drugs while monitoring the cells. After reaching steady state
at ± 90 min, either cyclosporin-A at a final concentration of
3 ELM, or medium was added to the incubation medium. Drug
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accumulation was then measured for another 30 min. For
each cell, three parameters were recorded upon excitation
which 0.6W of 488-nm laser light: forward and perpen-
dicular light scattering (through 488-nm band pass filters),
and daunorubicin fluorescence (through a 550-nm long pass
filter). The microcomputer controlling the flow cytometer
stored the data of 2,000 cells at 35 preselected time points
before and after the addition ofdaunorubicin or MDR rever-
sal agents. The collected data set can be used to select for
specific subpopulations of cells, and to determine accumula-
tion of daunorubicin in cells from these subpopulations
(Nooter et al., 1983). The carcinoma cells were distinguished
from contaminating hemopoietic cells by gating on the scat-
tering parameters. Dead cells were identified by counterstain-
ing with the non-vital dye Hoechst 33258 and were excluded
during the analysis. In the drug accumulation curves, the
mean daunorubicin fluorescence of the tumour cell sub-
population (calculated at each of the 35 time points of data
collection) is plotted vs the time after addition of the drug.
The difference in net uptake is calculated by the equation
FIDss - FIDCyA
FlDCYA
were F1Dss= relative daunorubicin fluorescence at steady
state after cyclosporin-A addition, and FIDCyA= relative
daunorubicin fluorescence at the start ofcyclosporin-A addi-
tion.
Clinical study
A phase II study of the combination of epidoxorubicin and
cyclosporin-A was performed. Patients were eligible if they
had a histological or cytological diagnosis of colorectal
cancer with measurable metastatic lesions. Age limits were
18-75 years; WHO performance score of < 2 was required.
One previous line of chemotherapy was allowed. WBC had
to be >4 x 1091-, platelets >100 x 1091-, serum creati-
nine < 120gimol l- I and serum bilirubin <25jtmol 1-' at the
start of the study treatment. Oral informed consent was
obtained from all patients. Treatment consisted of cyclo-
sporin-A 3mgkg-' in 100ml of dextrose 5% as an i.v.
infusion of 1 h given twice on day 1, at 7 and 1 h before
epidoxorubicin. Epi-doxorubicin 90 mg m 2 was administered
by i.v. bolus. All patients received antiemetics. Cycles were
repeated every 3 weeks. Retreatment was to be postponed for
1 week if at day 21 WBC was <3 x 1091- and/or platelets
<100 x 109 1-'. If hematological recovery was not complete
after 1 week of delay, dose reductions were prescribed. For
the first two cycles weekly follow up, including hematology
parameters and blood biochemistry, was done.
Responses were evaluated after two cycles of treatment
and defined according to standard WHO criteria.
The given dose ofcyclosporin-A had been shown in a pilot
study (unpublished data) to yield peak cyclosporin levels of
more than 3,000fig '-l and more than 1,000gAg 1-118 h later.
In vitro, even in the most resistant cells MDR could be
overcome by these concentrations of cyclosporin-A (Silber-
mann, 1989). Cyclosporin-A blood levels were monitored by
Cyclo-TRAC radioimmunoassay (IncStar Corporation, Am-
sterdam, The Netherlands) (Holt et al., 1988).
Results
In vitro drug uptake studies
Single cell suspensions of colon carcinoma cells were ob-
tained from ascites from four patients, later entered into the
phase II study.
Drug accumulation curves are shown in Figure 1. In this
figure, the mean drug accumulation of the carcinoma cells is
plotted vs the time after addition of daunorubicin. Upon
addition of cyclosporin-A an increase in daunorubicin ac-
cumulation could be measured in cancer cells from all four
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Figure 1 Daunorubicin accumulation (expressed as DNR fluor-
escence intensity in arbitrary units) by colorectal cancer cells in
vitro, obtained from ascites. At t =0, daunorubicin was added to
the cell suspensions (final concentration, 21M). The arrows in-
dicate the time point of addition ofCylcosporin A (final concen-
tration, 311M, (C)) or medium (M).
patients. Increases measured were 58, 37, 33 and 14%,
respectively.
Phase IIstudy
Twenty-four patients entered the study and were eligible and
fully evaluable. Median age was 56 years (range 27-74), 13
patients were males, 11 were females, median WHO perfor-
mance score was one (range 0-2). Eleven patients had
received prior chemotherapy, but none of them had received
drugs implicated in MDR. The median number of treatment
cycles given was three (range 1-7). the median cyclosporin-A
peak level was 6,248 ngml' (range 3,340-13,510) and the
median 18h level was 1,012ngml-l (range 301-5,020).
Cyclosporin-A infusion caused flushing in seven patients
(29%), assumed to be related to the vehicle. No other
cyclosporin-A related toxicities were noted. Chemotherapy
related side effects are tabulated in Table I. Of note, an
unexpected 33% of grade 3-4 leucocytopenia was observed.
One partial response (4%), lasting 6 months, was achieved in
a non-pretreated patient; 14 patients had stable disease
(median duration 3 months, range 3-8 months) and nine
showed tumour progression (including respectively two and
two patients with positive in vitro findings).
Discussion
In a study from Goldstein et al. (1989) 85% of 41 non-
pretreated colorectal tumours were found to have high mdrl
mRNA levels, suggesting that at least a part of the clinical
resistance ofthese tumours might be explained by an intrinsic
multidrug resistance phenotype. By on-line flow cytometry
we are able to test the activity of the P-170 glycoprotein
drug-efflux pump, the presence ofwhich is increased in MDR
(Pastan & Gottesman, 1987).
Anthracycline drug accumulation can be accurately mea-
sured using the technique offlow cytometry (Herweijer et al.,
1989; Nooter et al., 1983; Nooteret et al., 1989). The major
advantages of the use of flow cytometry to measure anthra-
cycline drug accumulation are the ability to discriminate
between several subpopulations of cells present in a sample,
and the possibility to quantitate drug accumulation in large
numbers of cells, resulting in more accurate figures. The
extension of this technique in on-line flow cytometry enables
accurate measurement of complete drug accumulation curves
over long periods of time (up to a few hours), and enables
monitoring ofeffects of the addition of reversal agents on the
drug accumulation of MDR cells (Herweijer et al., 1989;
Nooter et al., 1989; Silbermann et al., 1989). Using various
methods, it has been shown that cyclosporin-A can restore
the defective drug accumulation characteristic of MDR cellsEPIDOXORUBICIN + CY-A IN COLORECTAL CANCER 363
Table I Chemotherapy related side effects (24 patients)
WHO grade Nausea/vomiting Alopecia Leucopenia Thrombocytopenia
o 2 (8%) - 7 (29%) 17 (71%)
1 _ _ 5 (21%) 1 (4%)
2 6 (25%) - 4 (17%) 4 (17%)
3 16 (67%) 24 (100%) 1 (4%) 1 (4%)
4 - 7 (29%) 1 (4%)
WBC x 1091' Plat x 109 1-'
0 None None > 3.5 > 100
1 Mild Minimal 3-3.5 75-99
2 Moderate Moderate 2-2.9 50-74
3 Severe Complete 1-1.9 25-49
4 Requiring Irreversible > 1 <25
hospitalisation
in vitro (Herweijer et al., 1989; Nooter et al., 1989; Silberman
et al., 1989). It has also been shown the cyclosporin-A can
effectively restore the cytotoxicity of anthracycline drugs in
MDR cells in vitro (Twentyman et al., 1987) and in vivo
(Slater et al., 1986). The efficacy of reversal agents can be
studied by comparing the drug accumulation of MDR cells
in the presence and absence of specific reversal agents. In this
study we determined the effects of reversal agents on the
daunorubicin accumulation characteristics of colon car-
cinoma cells in vitro.
For such studies cell suspensions of intact tumour cells are
required, that can be obtained in case of pleural fluid or
ascites. Although the number ofexperiments is limited due to
the low occurrence of colorectal cancer patients with pleural
fluid and/or ascites, our data with on-line-flow cytometry in
four patients suggest that adequate concentrations of cyclo-
sporin-A can increase the intracellular drug concentration of
anthracyclines in vitro. In an in vitro study (Silberman et al.,
1989) a dose-response relationship was found for cyclo-
sporin-A to circumvent MDR in cell lines with different
levels of resistance. Projecting these in vitro data to the in
vivo situation we felt that for the clinical study the achieve-
ment of a peak cyclosporin blood level of 3,000fig 1-I and a
level of 1,000 g 1' after approximately one half-life of the
chosen cytotoxic drug would suffice, also in view of a positive
pilot experiment in a leukemia patient (Sonneveld & Nooter,
1990). Another pilot experiment had indicated that the aimed
blood levels could be achieved by the infusion schedule used.
A longer exposure to cyclosporin-A was deliberately avoided
in order not to have immunosuppressive effects. The toxicity
observed from cyclosporin-A was restricted to hot-flushes,
presumably related to the cremaphore and not to the actual
drug. The number of patients with severe leucocytopenia is
remarkably higher than expected with this dose of epidox-
orubicin (van Oosterom et al., 1984) and suggests some
influence of the addition of cyclosporin-A. As normal white
blood cells are known to lack increased P-170 glycoprotein
expression, other mechanisms may be involved in this in-
crease of toxicity. However, in vitro nor in vivo data to
explain this observation are available. The reasons for the
failure of the given treatment remain speculative, such as: (1)
intrinsic inactivity of epidoxorubicin in colorectal cancer
precluding cytotoxicity even at increased intracellular accum-
ulation, (2) inadequate cyclosporin-A concentrations at the
site of the tumour cells, despite high blood levels (this could
for instance be due to the ± 80% binding of cyclosporin-A
to plasma lipoproteins in man, if the MDR reversing effect is
only related to unbound drug, but no data on this topic are
available, (3) cyclosporin-A may not increase intracellular
epidoxorubicin levels in vivo in contrast to in vitro, (4) MDR
may just be a minor part of the many possible causes for
clinical resistance ofcolorectal cancers. Indeed the amount of
p-170 glycoprotein differs from cell to cell in a single tumour
(Fojo, 1989). Several of these postulations can only be
studied in an in vivo model, which development is awaited.
The presence clinical data also suggest that the interpretation
of the in vitro data should be cautious.
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